Compare HWBK & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | ELDN |
|---|---|---|
| Founded | 1865 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.0M | 291.8M |
| IPO Year | 1996 | 2014 |
| Metric | HWBK | ELDN |
|---|---|---|
| Price | $38.33 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 14.8K | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 31.42 | 30.67 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.10 | $1.35 |
| 52 Week High | $40.36 | $4.60 |
| Indicator | HWBK | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 51.47 |
| Support Level | $33.09 | $3.69 |
| Resistance Level | $40.36 | $4.15 |
| Average True Range (ATR) | 1.10 | 0.23 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 38.84 | 34.65 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.